Report
Dominic Rose ...
  • Naresh Chouhan
EUR 4644.50 For Business Accounts Only

Material Downgrade Risk For CDMO's & Suppliers (17 pgs)

Following recent news from Catalent & Polypeptide, our deep dive on the state of the CDMO and Bioprocessing Supplier industry shows that inventories have soared as sales were pulled forward & slow biotech funding will likely diminish demand for 1H23. At the same time, supply has expanded and energy, input & labour costs are all going up. We believe that book-to-bill ratios will likely stay below 1.0 until at least Q123 for many co’s. As a result, margins will come under pressure from softer pricing power and excess supply will lead to lower utilisation and increasing costs. Sartorius Stedim is most exposed in our view & we are 7% below consensus EBITDA in 2023 forecast close to zero EBITDA growth.
For access to the full note, please contact Naresh Chouhan ( )
Underlyings
Catalent Inc

Catalent is a holding company. Through its subsidiaries, the company is a provider of delivery technologies and development solutions for drugs, biologics and consumer health products. The company operates in four segments: Softgel Technologies, which provides formulation, development and manufacturing services for soft capsules; Biologics and Specialty Drug Delivery, which provides drug substance development and manufacturing; Oral Drug Delivery, which provides various formulation development and manufacturing technologies; and Clinical Supply Services, which provides manufacturing, packaging, storage, distribution, project management, and inventory management for drugs and biologics in clinical trials.

Lonza Group AG

Lonza supplies services and products that range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions. Co. operates in two segments: Lonza Pharma & Biotech, which clusters all of Co.'s offerings for pharmaceutical markets, focuses on providing custom development, custom manufacturing, cell therapy, viral therapeutics and bioscience solutions; and Lonza Specialty Ingredients, which includes offerings in its consumer care, agro ingredients, industrial solutions, wood protection and water treatment.

Merck KGaA

Merck is a global science and technology company based in Germany. Co. diversifies its activities into four business divisions: Merck Serono, Consumer Health, Performance Materials and Merck Millipore. The Merck Serono develops, manufactures and markets prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and selected cardiovascular and metabolic diseases. The Consumer Health manufactures and markets over-the-counter drugs addressing health themes such as mobility, women's and children's health, cough and cold. Performance Materials is a specialty chemicals business. The Merck Millipore is the supplier of products and services for the life science industry.

Sartorius Stedim Biotech SA

Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is engaged in serving science. The company's segments include: Life Sciences Solutions, which provides reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments, which provides instruments, consumables, software and services that are used for a range of applications in the laboratory, on the production line and in the field; and Specialty Diagnostics, which provides diagnostic test kits, reagents, culture media, instruments and associated products for customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.

WUXI BIOLOGICS CAYMAN INC

Provider
New Street Research
New Street Research

Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.

New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:

  • Pan European Telecom Services and Cable
  • US Telecoms, Cable, Satellite and Towers
  • Global Emerging Market Telecoms
  • Japan Telecoms
  • Asian Internet
  • Pan European Healthcare
  • Global healthcare thematic research

We provide debt research on:

  • Pan European Telecom Services and Cable


Analysts
Dominic Rose

Naresh Chouhan

Other Reports on these Companies
Other Reports from New Street Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch